CardioKinetix debuts Parachute device in China

October 21, 2013 by Chris Walker

Two patients in Beijing are treated for heart failure with CardioKinetix's catheter-based Parachute ventricular partitioning device.

CardioKinetix debuts Parachute device in China

CardioKinetix said its Parachute ventricular partitioning device was used to treat 2 patients in Beijing.

The Parachute device is used to restore damage to the left ventricle after a heart attack by partitioning the space to its usual geometry and function, according to a press release.

Last month, Menlo Park, Calif.-based CardioKinetix announced the 1st use of the Parachute device in Asia, after it was used to treat a patient in Malaysia. The device won CE Mark approval in the European Union and is undergoing a pivotal trial in the U.S. under an investigational device exemption from the FDA.

Sign up to get our free newsletters delivered straight to your inbox

"These initial cases in China mark another key milestone in CardioKinetix's journey to bring Parachute to heart failure patients around the world. China represents a key strategic opportunity for the company as we further our international expansion," CardioKinetix president & CEO Maria Sainz said in prepared remarks.